Kalpesh Patel, MD
Urology · Tucson, AZNPI 1386649911
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Olympus America Inc. at 28.1% of the total. Reporting peaked in 2022 at $7,000 and has fallen 68.2% since, to $2,223 in 2025. Among urology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $77.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$7K
- Neotract Inc.$4K
- Boston Scientific$3K
- AstraZeneca$2K
- Procept Biorobotics Corporation$1K
- Provepharm Inc.$1K
- plus $7K from 39 others
Across 331 payments — averaging $6730.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$733K
- Provepharm Inc.$428K
- AstraZeneca$154K
- Bayer$144K
- Urogen Pharma, Inc.$121K
- Ferring Pharmaceuticals AS$121K
- plus $527K from 12 others
What the payments were for
- Consulting fees$7,68329%
- Speaking & faculty fees$2,96011%
- Travel & lodging$3,97915%
- Food & beverage$11,70044%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iTIND System$5,978
- UroLift$3,238
- REZUM$2,885
- LYNPARZA$1,628
- AquaBeam Robotic System$676
- Dornier MedTech$590
- TITAN$461
- AQUABEAM SYSTEM$310
- CVAC$188
- Prolaris$129
- PROVENGE$125
- BOTOX$125
- Axonics$123
- XIAFLEX$122
- JELMYTO$122
- Nanoknife$120
- ORGOVYX$111
- Erleada$110
How this compares
$26,402 in reported general payments places this provider in the 90th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 83 | $220,540 |
| MyrbetriqMirabegron | 98 | $72,045 |
| GemtesaVibegron | 29 | $28,021 |
| Abiraterone Acetate | 21 | $27,978 |
| Mirabegron ErMirabegron | 16 | $5,287 |
| Tamsulosin Hcl | 326 | $4,122 |
| Finasteride | 274 | $3,672 |
| Oxybutynin Chloride ErOxybutynin Chloride | 93 | $1,401 |
| Dutasteride | 46 | $1,290 |
| Solifenacin Succinate | 20 | $700 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $578 |
| Cephalexin | 129 | $573 |
| Bethanechol Chloride | 11 | $372 |
| Oxybutynin Chloride | 22 | $320 |
| Imipramine Hcl | 22 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $463 | $248,561112 claims |
| Astellas Pharma US IncMyrbetriq | $233 | $72,04598 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 269 urology providers in Arizona.
Other urology in Tucson
- Mitzi BarmatzTucson$135K
- Curtis DunsheeTucson$46K
- Susan KalotaTucson$30K
- Tristan BerryTucson$14K
- Aleksandar BlubaumTucson$11K
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
- Rahul MehanMesa$277K
- Chinedu MmejeGilbert$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.